key: cord-0899874-or9jkb2a
authors: Patankar, S. B.; Rangnekar, H.; Joshi, K.; Suryawanshi, K.; Soni, P.; Gorde, A.; Shah, T.; Patankar, S.; Jha, D.; Raje, R.
title: Efficacy and Safety of Polyherbal formulation as an add-on to the standard of care in mild to moderate COVID-19: A randomized, double-blind, placebo-controlled trial
date: 2021-05-14
journal: nan
DOI: 10.1101/2021.05.14.21256900
sha: dce4283a81040317b70734fd025fbc126be307e9
doc_id: 899874
cord_uid: or9jkb2a

ABSTRACT Objective: To assess the efficacy and safety of polyherbal formulation (designated as IP) in comparison to placebo as add on to the standard of care (SoC) among patients with mild to moderate novel corona virus disease 2019 (COVID-19) Methods: Laboratory proved patients of mild to moderate COVID-19 disease were randomized to either placebo or IP as an add-on to SoC. Using quantitative reverse transcription-polymerase chain reaction (qRTPCR), we assessed the effect on viral load (VL). Change in immunological parameters such as blood lymphocyte subset, serum immunoglobulin was determined. The clinical improvement was assessed using a numerical rating scale (NRS) and WHO ordinal scale. Patients were followed for 30 days after randomization. Results:In total, 72 patients were randomized to either placebo (n=33) and IP (n=39). Fifty-two patients (n=21 in placebo and n=31 in IP arm) had qRT-PCR on day 0 and day 4. There was significant reduction in VL in IP arm (from 662081 copies/mL on day 0 to 48963 copies/mL on day 4; p=0.002)) but not in the placebo arm (from 385670 copies/mL on day 0 to 66845 copies/mL on day 4, p=0.106). Change in the NRS score and WHO ordinal scale score was significant in both treatment arms. However, the difference between the two groups was statistically significant in favour of drug group, . The increase in Th1 response was significant in the IP arm (p=0.023) but not in the placebo arm (p=0.098), thus implying immunomodulatory activity in the drug. No safety concerns were observed in any of the trial participants. Conclusion: This study finds that polyherbal formulation reduces viral load and contributes to immunomodulation and improvement in clinical conditions when used as add-on to the standard care in patients with mild to moderate COVID-19 without any side effects. These findings need to be further confirmed in a large, prospective, randomized study. Keywords: COVID-19, herbal medication, viral load, immuno modulation.

Novel coronavirus disease 2019 pandemic is a significant contributor to morbidity and 29 mortality in affected individuals. World Health Organization, as of 23April 2021, reports 144,358,956 30 confirmed cases of including 3, 066, 113 deaths [1] . Since its first identification in 31

December 2019, there is now a fair understanding of the COVID-19 disease pathogenesis. Hyper 32 stimulated immune response causing systemic inflammatory response syndrome or "cytokine storm" 33 is known to be implicated in progression to severe 3] . Such immune response correlates 34 linearly with the viral load that in turn correlates with disease severity [4, 5] . Modulating the immune 35 response in COVID-19 is now an established treatment approach. The RECOVERY trial showed that 36 dexamethasone 6 mg once daily for ten days significantly lowered 28-day mortality in hospitalized 37 COVID-19 patients [6] . Also, treatment with specific interleukin -6 inhibitor tocilizumab did not 38 improve survival but reduced the likelihood of progression to the composite outcome of mechanical 39 ventilation or death [7] . With Itolizumab, an anti-CD6 humanized monoclonal antibody with an 40 immunomodulating action on Teffector cells, there was a significant reduction in 30-day mortality 41 along with significant improvement in clinical immunological, and oxygen parameters [8] . Thus, 42 modulating immune response can help to improve clinical parameters and mortality outcomes, 43 especially in hospitalized moderate to severe COVID-19 patients. 44

Herbal formulations have long been assessed for their potential immune modulating effects [9, 10] . In 45 an in-vitro study (data on file), we observed that a combination of herbals (IP) such as Ashwagandha 46 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 clinical trial registry of India (CTRI/2020/07/026570).The study protocol was published in a peer-70 reviewed journal [11] . 71

Patients with a known positive status of RT-PCR for SARS-CoV-2 disease were screened for the 73 study. Eligible and consenting patients were enrolled. Patients were randomized using computer-74 generated randomization codes to receive either IP or placebo as an add-on to the recommended 75 investigational products were manufactured per API guidelines. Patients were advised to take one 81 capsule, two times a day (of each IP1 and IP2) or placebo, after meals. Patients received a prepacked 82 carton of study treatment for a total duration of 30 days. Capsule IP1 and IP2 were given for the first 83 15 days, and last 15 days they were given only IP2. Patients receiving placebo also received 2 84 capsules twice a day for first 15 days and for next 15 days, one capsule twice a day (Image 1). All the 85 patients continued their routine diet and physical activity and other prescribed treatment as per Indian 86

Council of Medical Research (ICMR) and World Health Organization (WHO) guidelines in 87 circulation at the time of study conduct. 88

During baseline visit (Day 0) nasopharyngeal swab was taken for qRTPCR, numerical rating scale 89 (NRS) was filled for clinical status and the blood was withdrawn for various immunological 90 inflammatory and safety markers. Patients had three follow-ups during the 30-day treatment period. 91

First follow-up visit was done at day 4±1. qRTPCR , NRS was repeated at this visit and any clinical 92 adverse events were recorded . Second follow-up was done clinically or telephonically (if they were 93 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.14.21256900 doi: medRxiv preprint discharged) on day 15±2 to record any clinical deterioration in clinical condition and to record 94 adverse effects if any. Last follow-up was at day 30±2 to document clinical condition, adverse effects 95 and perform laboratory investigations. In this last follow-up, study personnel visited patients in their 96 homes to avoid their repeat visit to site as it was active COVID-19 hospital. Patients were asked to 97 visit any time if they observed any deterioration in clinical condition or had developed any untoward 98

Quantitative estimation of viral load using qRTPCR 100

Three viral loci RdRP, N gene and E gene and a human gene as internal control (RNaseP) were 101 detected using GenePath Diagnostics' indigenously developed qRTPCR assay, CoViDx One v2.1.1 102 keeping appropriate controls and standards. Ten micro litres of extracted nucleic acid was used as an 103 input for the qRT-PCR. Quantitative estimation for each genomic target was performed using 104 standards, for which the number of genome copies were already known. The threshold cycle (Ct 105 value) for each genomic target was extrapolated to the viral load of standards to estimate the number 106 of copies/uL which were then converted to copies/mL for each gene for each sample. Average number 107 of copies/ ml was calculated for each sample that accounts for the approximate viral load in the 108 sample. Ct values for control human gene (RNaseP) ensured the adequacy of sample and served as 109 control for nucleic acid extraction and nucleic acid amplification. 110

On the day of first encounter with patients, they were subjected to thorough clinical and laboratory 111

investigations. After signing of informed consent, their demographic details, and clinical parameters 112 were recorded. Oxygen saturation was assessed using pulse oximeter. We investigated viral load (VL) 113 with quantitative RTPCR for COVID-19, and blood was drawn for lymphocyte subset analysis 114 (absolute neutrophil count, absolute lymphocyte count, TH1, TH2, Treg cells, NK Cells and CD 115 markers such as CD3, CD4, CD3: CD8 ratio) as well as serum IgG and IgM levels (not specific to 116 COVID-19). Liver function tests and renal function tests were performed as a part of safety 117 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.14.21256900 doi: medRxiv preprint assessment.. Blood investigations were repeated on day 30 for immunological markers, and for safety 118 assessments. We performed all the tests at a single accredited laboratory . 119

Primary efficacy outcome measure was change in viral load. Secondary efficacy outcome measures 121 were change in disease severity score and change in immunological and inflammatory markers. 122

Numerical Rating Scale (NRS) was used for overall disease severity. 0 was considered for normal, 1 123 to 3 for mild, 4 to 6 for moderate and 7 to 10 for severe severity of the disease. Patients were asked to 124 rate the disease severity on the NRS. Also, change in immunological parameters such as lymphocyte 125 subset analysis (TH1, TH2, Th17),NK Cells and CD markers, serum IgG and IgM levels and Covid19 126 antibodies were assessed. Inflammatory and other markers like C -reactive protein and D-Dimer, Sr. 127

Ferritin were assessed in a small portion of enrolled subjects. Primary safety measure was incidence 128 of adverse reactions (clinical and/or laboratory parameters). 129 S tatistical analysis: Sample size: . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.14.21256900 doi: medRxiv preprint or Fischer exact test. For continuous variables, normal distribution was assessed by plotting the 141 histograms. Normally distributed data was presented using mean and standard deviations (SD) and 142 non-normally distributed data presented as median (Interquartile range (IQR) 25-75). Student t-test 143

and Mann-Whitney U test were applied accordingly to test the statistical differences in continuous 144 independent variables. For before and after analysis, we used paired t test and Wilcoxon signed rank 145 sum test to determine the statistical significance. P value <0.05 was considered significant for all 146 comparisons. 147

Between August and September 2020, we screened 92 patients of which 72 were randomized to either 150 placebo (n=33) or IP (n=39). Figure 1 shows study flow of the participant. Overall, 66 patients 151 completed the 30-day follow-up (placebo n= 31; IP n=35). 152 (Table no. 

Mean age was 43 years and 47 years in placebo and IP group (p=0.336). There was no difference in 154

proportion of males and females in two groups (p=0.150). 155

Overall, 52 patients had undergone qRT-PCR on day 4 (31 in drug arm, 21 in placebo arm). IP 157 treatment was associated with significant reduction in median VL (from 662081 virus copies/mL 158 (IQR: 56904 to 19485712) on day 0 to 48963 copies/mL (IQR: 8774 to 1248257) day 4; p=0.002)). In 159 placebo group also, there was reduction in VL but it was non-significant (from 385670 copies/mL 160 (IQR: 30807 to 131511846) on day 0 to 66845 copies/mL (IQR: 11978 to 836124.5) on day 4 161 (p=0.106)). Standard of care was continued in both the groups. 162

Clinical Assessment (Table No. 3) 163 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.14.21256900 doi: medRxiv preprint

In the IP arm, there was significant reduction in NRS from day 0 to day 4 (4.3 (+1.13) 1.74+(1.03), 164 p<0.0001). In Placebo arm as well, there was significant reduction in NRS score (4.26+1.09 to 165 3.16+1.03, p<0.0001). Baseline scores of both the groups were similar, with P value 0.78; the 166 difference between drug and placebo arm of 'after' was statistically highly significant. Later, upon 167 WHO ordinal scale was available, and retrospectively the scores were assigned to the patients' 168 condition, on day 0 and 4, IP arm was at 1.63 (+0.84) and 1.03 (+0.45) respectively with p value 169 0.0001; whereas, for placebo, these values were 1.71 (+0.78)and 1.26 (+0.63) with p value 0.03. P 170 value for drug arm was highly significant (>0.01). 171

Changes in the inflammatory and immunological parameters are shown in Table4, between day 0 and 173 day 30. There was significant increase in absolute B cell count, absolute T cell count, absolute CD3, 174

CD4 and T helper cells as well as in the ratio of absolute CD3 and CD8 cells in both IP and placebo 175 arm. Change in absolute NK cell count was significant in placebo arm (p=0.020) but not in drug arm 176 (p=0.067). However, the magnitude of change was higher with IP than the placebo. The increase in 177

Th1 response was significant with IP treatment (p=0.023) but not with the placebo treatment 178 (p=0.098). The IgG antibodies reduced significantly in both placebo and IP arm. However, the effect 179 on IgM was non-significant in both groups. Covid antibodies were done on day 30. P value was not 180 significant, however around 20% more antibodies were noted in drug arm than placebo arm. Due to 181 inadequate sample size for CRP, D Dimer analysis was not feasible, however, average 50% reduction 182 in CRP was seen in SoC + drug arm whereas increase in the SoC + Placebo arm was seen. Similar 183 trend was seen for D Dimer also. Less number of patients opted for blood withdrawal during follow-184 up visits, and majority of them denied the blood letting. 185

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.14.21256900 doi: medRxiv preprint There were no serious adverse events in the drug arm. One SAE occurred in placebo (+SoC) 187 arm, which was 'prolongation of hospitalization' due to Covid related pneumonia, which got 188 resolved later. LFT, RFT were not deranged in any of the patient, confirming safety. No 189 drug-drug interaction with the SoC was seen.

Since December 2019, COVID -19 pandemic has been around the globe affecting millions of 192 individuals with significant contribution in morbidity and mortality. Despite being present for over a 193

year, definite therapies are limited for COVID-19. Modulating immunological response with steroids 194 has been found beneficial in hospitalized patients. However, in a large majority of patients who have 195 mild to moderate disease, effective treatment is necessary to prevent disease progression as well as 196 shedding of the virus to lower the transmission rates. Thus, reducing the viral load may assist in 197 achieving this objective. Viral load independently correlates with the risk of intubation and in-hospital 198 mortality [12, 13] . We observed that IP was associated with significant reduction in viral load at day 4. 199

Reducing the viral load can help in early symptom recovery. It was evident as NRC was significantly 200

Anti-viral activity of IP therefore can be helpful in early recovery of mild to moderate COVID-19 202 patients. Among currently employed antiviral agents, early treatment with favipiravir was reported to 203 be associated with lower in VL at day 6 In hospitalized patients with . 204

Another antiviral agent that is used widely is remdesivir. However, remdesivir did not appear to affect 205 rates of viral RNA load decline and mortality when compared with placebo in severe hospitalized 206 COVID-19 patients [15] . Thus, initiating an antiviral agent before the peak viral load might be 207 necessary. It may be difficult in clinical situation to predict the time of peak VL. In this study, IP was 208 initiated as soon as individuals were tested positive for COVID-19 which might have helped in earl y 209 improvement in clinical NRS score. 210 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.14.21256900 doi: medRxiv preprint

In addition to lowering VL, modulating immune response is now an established strategy. In 211 inflammatory response, Th1 pathway is associated with increase in the release of proinflammatory [19, 20] .Though the 226 statistical significance was not reached, increase in the number of NK cells was higher in IP group 227 than that of placebo. It probably indicates a potential to preserve and enhance the NK cell function 228 that might assist in viral clearance. 229

The in-vitro study conducted with study drug with remdesivir used as a positive control for viral 230 inhibition. Inhibition of virus replication is determined based on the fold change in the Ct value in TS-231 treated cells compared to the control. After 24 hours, % inhibition of E-gene was 9.10% and of N 232 gene, it was 21.93%. After 48 hours, N gene inhibition was same as 24 hours however E gene was 233 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021.

further inhibited to 28.43% (data on file). Thus, clinical effects of viral load reduction identified with 234 qRT-PCR are supported by the in-vitro data. 235

Protocol of the study was published in BMC's 'Trials' (2020)21:943. It was for the first time Shankha (incinerated conch shell) Bhasma is helpful to tackle gastric symptoms related to the disease 255 and Jasath Bhasma (zinc oxide) has an antiviral activity [31] . Jasath Bhasma is the purified zinc from 256

Ayurvedic process to yield optimum effect of zinc supplementation. Due to antioxidant effects of 257 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.14.21256900 doi: medRxiv preprint Zinc, it protects against ROS and RNS. Zinc helps modulate cytokine release and induces 258 proliferation of T cells and helps to maintain skin and mucosal membrane integrity.Zinc has a central 259 role in cellular growth and differentiation of immune cells. It is essential for intracellular binding of 260 tyrosine kinase to T cell receptors, required for T lymphocyte development and activation. Zinc 261 supports Th1 response [32] . 262

When we discuss about the possible mechanism of action, the approach is such that the combination 263 acts 'as a whole'. There are multiple phyto-ingredients and a lot of chemical entities that act on 264 multiple targets in various systems of the body. By virtue of such entity-rich drug, a milieu is created 265 in the body, which is prepared to take care of the infection at multiple levels, organs and systems. 266

Since it has shown positive results in reducing viral load and immune modulation of TH1 response, 267 the same herbo-mineral formulation can have role for prophylactic action towards the virus. 268

Currently the formulation is known as Capsule CoviLyzer TM and Capsule Abayakasthaa plus R , and is 270 manufactured by Ishaanav Nutraceuticals Pvt. Ltd. 271

With COVID-19 pandemic being ongoing in 2021, search for potential antiviral therapies is ongoing. 273

This polyherbal combination drug was identified to provide effective antiviral activity in mild to 274 moderate COVID-19 patients. Potential immunomodulatory effects observed with drug can also assist 275 in preventing inflammatory tissue damage and may help reduce the intensity of systemic 276 inflammatory syndrome. The investigational drug was found to be safe with no serious adverse event 277

and it can be safely given along with Standard of Care to enhance its therapeutic activity in patients 278 with mild to moderate COVID-19 disease for reducing viral load, cytokine storm and clinical 279 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.14.21256900 doi: medRxiv preprint recovery. Another study on severely affected Covid patients would be worthwhile to explore of this 280 formulation, along with the standard of care. 281

The trial was funded by AMAI Trust, Pune 283

Dr. Suresh Patankar is member of AMAI trust. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.14.21256900 doi: medRxiv preprint

Image 1: Treatment administration in two groups 396 397 398 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.14.21256900 doi: medRxiv preprint Enrolment . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.14.21256900 doi: medRxiv preprint

Remdesivir in adults with severe 331

COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Distinguishable Immunologic 334 Characteristics of COVID-19 Patients with Comorbid Type 2 Diabetes Compared with 335

A review of immunomodulators 338 in the Indian traditional health care system

Potential of regulatory T-341 cell-based therapies in the management of severe COVID-19

Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm

Its Role in COVID-19

Efficacy of natural compounds from Tinosporacordifolia against 349

SARS-CoV-2 protease, surface glycoprotein and RNA polymerase